Xencor Inc
$ 20.81
4.05%
07 Aug - close price
- Market Cap 1,547,294,000 USD
- Current Price $ 20.81
- High / Low $ 21.05 / 19.93
- Stock P/E N/A
- Book Value 8.84
- EPS -2.23
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.17 %
- ROE -0.29 %
- 52 Week High 21.96
- 52 Week Low 6.92
About
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of cytokine and monoclonal antibody therapies designed to treat cancer patients and autoimmune diseases in the United States and internationally. The company is headquartered in Monrovia, California.
Analyst Target Price
$28.17
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-05 | 2026-05-06 | 2026-02-25 | 2025-11-05 | 2025-08-06 | 2025-05-07 | 2025-02-27 | 2024-11-06 | 2024-08-05 | 2024-05-09 | 2024-02-27 | 2023-11-07 |
| Reported EPS | -0.29 | -1.71 | -0.09 | -0.08 | -0.41 | -0.66 | -0.62 | -0.71 | -1.07 | -1.11 | -0.31 | -0.4 |
| Estimated EPS | -0.82 | -0.75 | -0.6037 | -0.72 | -0.71 | -0.58 | -0.7862 | -1.02 | -0.79 | -0.77 | -0.09 | -0.71 |
| Surprise | 0.53 | -0.96 | 0.5137 | 0.64 | 0.3 | -0.08 | 0.1662 | 0.31 | -0.28 | -0.34 | -0.22 | 0.31 |
| Surprise Percentage | 64.6341% | -128% | 85.0919% | 88.8889% | 42.2535% | -13.7931% | 21.1397% | 30.3922% | -35.443% | -44.1558% | -244.4444% | 43.662% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: XNCR
2026-08-07 07:11:48
Xencor, Inc. (NASDAQ:XNCR) has received a consensus "Hold" recommendation from brokerages, with nine firms providing ratings. The biopharmaceutical company recently reported a quarterly loss of $0.29 per share, exceeding analyst estimates, and saw its revenue increase by 17.4% year over year. Several institutional investors have also significantly increased their holdings in Xencor.
2026-08-06 18:11:48
Xencor, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2025, highlighting advancements in its oncology and autoimmune disease pipelines. Key updates include the progress of XmAb819 in clinical trials for various cancers, the advancement of XmAb942 and XmAb412 for inflammatory bowel disease, and an anticipated cash runway through 2028. The company also noted a significant increase in revenue for the full year 2025 and a reduced net loss compared to the previous year.
2026-08-06 17:10:56
Xencor, Inc. reported mixed Q2 and half-year 2026 results, with a narrowing net loss for the quarter but a widened net loss for the first six months. This financial divergence highlights the impact of R&D spending on the company's profile and prompts a re-evaluation of its investment narrative, particularly concerning funding needs and spending discipline. The article emphasizes that while the Q2 improvement is positive, the higher year-to-date deficit keeps the focus on funding and trial execution risks related to Xencor's key clinical programs like XmAb942 and XmAb412.
2026-08-06 15:10:56
Xencor (NASDAQ:XNCR) shares reached a new 52-week high after reporting better-than-expected quarterly earnings and revenue. The biopharmaceutical company posted an EPS of $(0.29), significantly beating the consensus estimate of $(0.80), and revenue of $51.22 million, surpassing expectations. Despite remaining unprofitable with a negative net margin, analysts maintain a "Moderate Buy" rating with an average price target of $24.62, and several institutional investors have increased their positions.
2026-08-06 04:15:13
Xencor, Inc. reported its second-quarter 2026 financial results, highlighting significant progress in its clinical pipeline and strategic partnerships. Key updates include planned presentations for XmAb819 at ESMO 2026, continued enrollment for XmAb942 in the XENITH-UC study, and the initiation of a first-in-human study for XmAb412. The company also announced a $105 million settlement with Alexion and a $10 million milestone payment from Zenas BioPharma, projecting sufficient cash resources to fund operations through 2028.
2026-08-05 23:10:57
Xencor (NASDAQ: XNCR) reported a Q2 2026 net loss of $21.7 million, narrowing from $30.8 million in Q2 2025, on revenues of $51.2 million. The company also announced a post-quarter-end settlement with Alexion for $105 million, resolving a U.S. royalty dispute related to Ultomiris while retaining ex-U.S. royalty rights. Xencor's cash and marketable securities stood at $486.4 million as of June 30, 2026, and the company projects these funds to cover operations for at least 12 months.
